136 related articles for article (PubMed ID: 11237260)
21. Kinetics of interactions between DNA and topoisomerase II in the presence of physiologically active effectors.
Favorov PV; Yakubovskaya EA; Reshetnyak AV; Gabibov AG
Dokl Biochem; 2000; 370(1-6):38-41. PubMed ID: 11977249
[No Abstract] [Full Text] [Related]
22. Topoisomerase II-dependent novel antitumor compounds merocil and merodantoin induce apoptosis in Daudi cells.
Gulliya KS; Franck B; Schneider U; Sharma R; Arnold L; Matthews JL
Anticancer Drugs; 1994 Oct; 5(5):557-66. PubMed ID: 7858288
[TBL] [Abstract][Full Text] [Related]
23. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
Kreuzer KN
Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of bent metallocenes: electronic structure analysis using DFT computations.
Senthilnathan D; Vaideeswaran S; Venuvanalingam P; Frenking G
J Mol Model; 2011 Mar; 17(3):465-75. PubMed ID: 20495841
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors.
Galal SA; Hegab KH; Hashem AM; Youssef NS
Eur J Med Chem; 2010 Dec; 45(12):5685-91. PubMed ID: 20884089
[TBL] [Abstract][Full Text] [Related]
26. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
27. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction.
Matsumoto SS; Haughey HM; Schmehl DM; Venables DA; Ireland CM; Holden JA; Barrows LR
Anticancer Drugs; 1999 Jan; 10(1):39-45. PubMed ID: 10194546
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
29. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
O'Reilly EK; Kreuzer KN
Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
[TBL] [Abstract][Full Text] [Related]
30. Transcription generates positively and negatively supercoiled domains in the template.
Wu HY; Shyy SH; Wang JC; Liu LF
Cell; 1988 May; 53(3):433-40. PubMed ID: 2835168
[TBL] [Abstract][Full Text] [Related]
31. Enantiomeric specificity of biologically significant Cu(II) and Zn(II) chromone complexes towards DNA.
Arjmand F; Jamsheera A; Afzal M; Tabassum S
Chirality; 2012 Dec; 24(12):977-86. PubMed ID: 23001645
[TBL] [Abstract][Full Text] [Related]
32. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.
Wilstermann AM; Osheroff N
Curr Top Med Chem; 2003; 3(3):321-38. PubMed ID: 12570766
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
Vashisht Gopal YN; Konuru N; Kondapi AK
Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone.
Vance JR; Bastow KF
Biochem Pharmacol; 1999 Aug; 58(4):703-8. PubMed ID: 10413309
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.
Li PH; Jiang H; Zhang WJ; Li YL; Zhao MC; Zhou W; Zhang LY; Tang YD; Dong CZ; Huang ZS; Chen HX; Du ZY
Eur J Med Chem; 2018 Feb; 145():498-510. PubMed ID: 29335211
[TBL] [Abstract][Full Text] [Related]
37. Supercondensed structure of plasmid pBR322 DNA in an Escherichia coli DNA topoisomerase II mutant.
Huang XT; Chen X
J Mol Biol; 1990 Nov; 216(2):195-9. PubMed ID: 2174973
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
Vashisht Gopal YN; Jayaraju D; Kondapi AK
Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
[TBL] [Abstract][Full Text] [Related]
39. The role of ring D in the antitumour antibiotic streptonigrin: metal complexation, DNA binding and topoisomerase inhibition by ABC ring analogues of streptonigrin.
Anderberg PI; Harding MM
Anticancer Drug Des; 2001; 16(2-3):143-53. PubMed ID: 11962512
[TBL] [Abstract][Full Text] [Related]
40. Dual topoisomerase I and II poisoning by chiral Ru(II) complexes containing 2-thiophenylimidazo[4,5-f][1,10]phenanthroline derivatives.
Wang YC; Qian C; Peng ZL; Hou XJ; Wang LL; Chao H; Ji LN
J Inorg Biochem; 2014 Jan; 130():15-27. PubMed ID: 24145066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
